11C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma

Oncotarget

Volumn 6, Issue 10, 2015, Pages 8418-8429

  Lückerath, Katharina ^a   Lapa, Constantin ^a   Albert, Christa ^a   Herrmann, Ken ^a   Jörg, Gerhard ^a   Samnick, Samuel ^a   Einsele, Herrmann ^a   Knop, Stefan ^a   Buck, Andreas K ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

11C Methionine PET; Molecular imaging; Multiple Myeloma; Treatment response

Indexed keywords

BORTEZOMIB; CARFILZOMIB; FLUORODEOXYGLUCOSE F 18; IXAZOMIB; METHIONINE C 11; SYNDECAN 1; CARBON-11 METHIONINE; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; DIAGNOSTIC IMAGING; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; METHIONINE; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS;

EID: 84928395351     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3053     Document Type: Article

References (28)

1. de la Puente P, Muz B, Azab F, Luderer M, Azab AK. Molecularly targeted therapies in multiple myeloma. Leuk Res Treatment. 2014; 2014:976567. Epub 2014/05/16.
2. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014; 32:587-600. Epub 2014/01/15.
3. Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014; 2014:864058. Epub 2014/05/08.
4. Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intraclonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014; 165:441-454. Epub 2014/03/04.
5. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002; 43:1457-1463. Epub 2002/11/02.
6. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013; 162:50-61. Epub 2013/04/27.
7. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr., van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009; 114:2068-2076. Epub 2009/05/16.
8. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005; 184:1199-1204. Epub 2005/03/25.
9. van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. F-fluorodeoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2011; 118:1971-1981. Epub 2011/09/03.
10. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011; 118:5989-5995. Epub 2011/09/09.
11. Lapa C, Lueckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, et al. 18FDG-PET/CT for Prognostic Stratification of Patients with Multiple Myeloma Relapse after Stem Cell Transplantation. Oncotarget. 2014; in press.
12. Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R, et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica. 2014; 99:629-637. Epub 2014/04/02.
13. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol. 2011; 29:1907-1915. Epub 2011/04/13.
14. Lueckerath K, Lapa C, Spahmann A, Jorg G, Samnick S, Rosenwald A, et al. Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology. PLoS One. 2013; 8:e84840. Epub 2014/01/01.
15. Reijmers RM, Spaargaren M, Pals ST. Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. FEBS J. 2013; 280:2180-2193. Epub 2013/02/20.
16. Tagoug I, Plesa A, Dumontet C. Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol. 2013; 706:11-16. Epub 2013/03/06.
17. Udi J, Schuler J, Wider D, Ihorst G, Catusse J, Waldschmidt J, et al. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br J Haematol. 2013; 161:104-116. Epub 2013/02/07.
18. Nanni C, Zamagni E, Celli M, Caroli P, Ambrosini V, Tacchetti P, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013; 38:e74-79. Epub 2012/11/13.
19. Derlin T, Bannas P. Imaging of multiple myeloma: Current concepts. World J Orthop. 2014; 5:272-282. Epub 2014/07/19.
20. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19:3058-3065. Epub 2001/06/16.
21. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004; 22:900-908. Epub 2004/03/03.
22. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8:797-805. Epub 2007/8/19.
23. Nishizawa M, Nakamoto Y, Suga T, Kitano T, Ishikawa T, Yamashita K. C-Methionine PET/CT for multiple myeloma. Int J Hematol. 2011; 91:733-734. Epub 2010/05/15.
24. Nakamoto Y, Kurihara K, Nishizawa M, Yamashita K, Nakatani K, Kondo T, et al. Clinical value of (1)(1) C-methionine PET/CT in patients with plasma cell malignancy: comparison with (1)(8)F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40:708-715. Epub 2013/01/24.
25. Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, et al. Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT-Initial Experience. Radiology. 2007; 242:498-508. Epub 2006/12/21.
26. Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, et al. Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci. 2014. Epub 2014/09/16.
27. Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010; 99:217-225. Epub 2010/01/22.
28. Hansen CT, Pedersen PT, Nielsen LC, Abildgaard N. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur J Haematol. 2014. Epub 2014/05/09.